

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

DELAY IN DESPATCH OF 2019 ANNUAL REPORT

Reference is made to the annual results announcement of The United Laboratories International Holdings Limited (the “Company”) for the year ended 31 December 2019 dated 30 March 2020.

Due to the outbreak of COVID-19 pandemic and the relevant quarantine measures and travel restrictions for relevant personnel of the Company in China, the bulk-printing of the annual report for the year ended 31 December 2019 (the “2019 Annual Report”) was affected. It is expected that the 2019 Annual Report will be published and despatched to the shareholders of the Company on or before 8 May 2020.

By Order of the Board

The United Laboratories International Holdings Limited

Tsoi Hoi Shan

Chairman

Hong Kong, 29 April 2020

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.